Diabetic nephropathy arises from chronic hyperglycaemia-induced damage to the renal microvasculature, manifesting initially as glomerular hyperfiltration and microalbuminuria. Persistent metabolic ...

Diabetic nephropathy arises from sustained hyperglycaemia, haemodynamic alterations and metabolic stress that converge on the glomerular microvasculature. Persistent high glucose levels promote ...

Panelists discuss how immunoglobulin A (IgA) nephropathy develops through a complex 4-hit cascade involving aberrant IgA1 glycosylation, anti-glycan antibody formation, immune complex deposition, and ...

A proliferation-inducing ligand (APRIL) is implicated in the pathogenesis of IgA nephropathy. Sibeprenlimab is a humanized IgG2 monoclonal antibody that binds to and neutralizes APRIL. In this phase 2 ...

The pathogenesis of IgA nephropathy is mediated by B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL). Telitacicept is a fusion protein that targets and neutralizes both BAFF ...

The global burden of diabetic nephropathy increased from 1990 to 2021, and is projected to continue increasing to 2050, according to a study published in Frontiers in Endocrinology. Xiao Ma, from The ...

Diabetic nephropathy is a complication of diabetes that affects the kidneys. Hyperkalemia refers to high levels of potassium in the blood. Damage to the kidneys can result in hyperkalemia. Diabetic ...

Diabetic nephropathy develops slowly over several years. There may be no symptoms in its early stages. Treatment may prevent it from progressing and leading to serious conditions, like end stage renal ...

Diabetic nephropathy has five stages that describe the progression of the disease from least to most severe. Diabetic nephropathy, also known as diabetic kidney disease, is a slowly progressing ...

Three large randomized trials tested a simple idea: if one blood-pressure drug that blocks the renin-angiotensin system protects diabetic kidneys, two such drugs should protect them better. Each trial ...